List of Excipients in Branded Drug MYLERAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Woodward Pharma Services LLC	MYLERAN	busulfan	69784-620	ANHYDROUS LACTOSE
Woodward Pharma Services LLC	MYLERAN	busulfan	69784-620	HYPROMELLOSES
Woodward Pharma Services LLC	MYLERAN	busulfan	69784-620	MAGNESIUM STEARATE
Woodward Pharma Services LLC	MYLERAN	busulfan	69784-620	STARCH, CORN
Woodward Pharma Services LLC	MYLERAN	busulfan	69784-620	TITANIUM DIOXIDE
Woodward Pharma Services LLC	MYLERAN	busulfan	69784-620	TRIACETIN

Myleran Excipient Strategy and Commercial Opportunities: Busulfan Formulation, Generic Entry, and IP Analysis

Last updated: August 8, 2026

Myleran is the former oral busulfan brand, supplied as a 2 mg film-coated tablet for chronic myeloid leukemia and other hematologic indications. Its commercial opportunity is no longer based on active compound patents or brand exclusivity. The opportunity is in reliable generic supply, low-dose content uniformity, stability, differentiated excipient systems, and potential 505(b)(2) reformulation strategies. The principal technical barrier is handling a potent cytotoxic active ingredient while maintaining dissolution, dose uniformity, packaging stability, and operator safety.

What is Myleran and which active ingredient does it contain?

Myleran contains busulfan, an alkylating agent that produces prolonged myelosuppression. The original product is an oral 2 mg tablet. Busulfan is also marketed in an intravenous formulation under the Busulfex brand, but Busulfex is a separate dosage form with different excipient, manufacturing, regulatory, and clinical requirements.

Attribute	Myleran
Active ingredient	Busulfan
Dosage form	Film-coated tablet
Strength	2 mg
Therapeutic class	Alkylating antineoplastic
Original route	Oral
Primary historical use	Chronic myeloid leukemia
Brand developer	Burroughs Wellcome, later part of GlaxoSmithKline
Current commercial status	Legacy product; generic and supply-chain considerations dominate
Key formulation issue	Low-dose potent cytotoxic compound requiring tight content uniformity
Main competing dosage form	Intravenous busulfan, including Busulfex

The Myleran label identifies conventional tablet excipients, including lactose, maize starch or pregelatinized starch, magnesium stearate, colloidal silicon dioxide, and film-coating components such as hypromellose and titanium dioxide, depending on the jurisdiction and product presentation.[1]

What excipients are used in Myleran tablets?

Myleran uses a conventional immediate-release tablet platform. The excipient system supports powder flow, granulation or compression, lubrication, tablet disintegration, and film coating.

Core tablet excipients

The principal excipient functions are:

Excipient class	Likely function in Myleran-type tablet	Commercial relevance
Lactose	Diluent and compressibility aid	Low cost, established regulatory history, but requires attention to patient intolerance and moisture behavior
Maize or pregelatinized starch	Binder, disintegrant, and filler	Supports tablet strength and rapid breakup
Magnesium stearate	Lubricant	Excessive use can slow wetting and dissolution
Colloidal silicon dioxide	Glidant and anti-caking agent	Supports uniform die filling at low drug loading
Hypromellose	Film former	Improves handling, appearance, and protection
Titanium dioxide	Opacifier and pigment	May affect marketability in jurisdictions with changing excipient policies
Purified water or solvent system	Processing aid for coating or granulation	Must be removed to validated residual limits

The exact excipient composition must be taken from the applicable national label and approved product dossier. Different historical Myleran presentations and generic busulfan products may use different grades or coating systems.

Why the excipient system matters at a 2 mg strength

A 2 mg tablet has a relatively low active-to-excipient ratio. Small variations in blending, segregation, lubrication, or compression can materially affect assay and content uniformity. A generic developer therefore needs to optimize:

• Particle-size distribution of busulfan and the diluent.
• Blend segregation during transfer and hopper residence.
• Sampling and in-process content-uniformity controls.
• Lubricant concentration and blending time.
• Compression force and tablet porosity.
• Disintegration and dissolution after accelerated aging.
• Containment during dispensing, granulation, compression, coating, and cleaning.

The formulation should be developed around a quality-by-design control strategy rather than simple excipient substitution. FDA’s ANDA guidance places particular importance on pharmaceutical equivalence, bioequivalence, drug-product quality, and control of critical manufacturing variables.[2]

What excipient strategy is most suitable for a generic Myleran product?

The lowest-risk strategy is a conventional immediate-release tablet that preserves the reference product’s key performance characteristics. A developer should avoid unnecessary formulation novelty unless the goal is to support a 505(b)(2) application or obtain a clinically meaningful product advantage.

Strategy 1: Reference-aligned lactose-starch tablet

A lactose-starch platform is likely to offer the shortest development path because it uses familiar, compendial excipients and a conventional manufacturing process. The principal benefits are:

• Broad regulatory precedent.
• Low excipient cost.
• Established tablet-processing behavior.
• Straightforward scale-up.
• Lower formulation-change risk.

The weaknesses are lactose dependence, potential moisture sensitivity, and limited differentiation from existing generic products.

Strategy 2: Lactose-free direct-compression tablet

A lactose-free formulation could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler. The commercial rationale would be improved excipient tolerance and access to institutional buyers with excipient restrictions.

The main development risks are altered density, flow, compactability, disintegration, and dissolution. A direct-compression design also requires strong control of particle-size distribution and segregation, particularly at the 2 mg strength.

Strategy 3: Co-processed excipient platform

A co-processed filler-binder, such as a cellulose-based or starch-based system, could improve flow and compression while reducing process steps. This may be useful for small-batch production or containment-focused facilities.

The commercial value is limited if the change produces no measurable improvement in supply reliability, stability, or manufacturing cost. The strategy is more attractive when the manufacturer owns a proprietary excipient-processing platform or needs to avoid a problematic reference excipient.

Strategy 4: Moisture-protective film coating and packaging

Busulfan is a cytotoxic small molecule, so chemical stability, packaging permeability, and operator protection are material considerations. A developer can evaluate:

• Low-permeability blister packaging.
• High-barrier bottles with desiccant.
• Improved tablet coating uniformity.
• Reduced coating moisture exposure.
• Unit-dose packaging for oncology pharmacies.
• Child-resistant and tamper-evident packaging.

Packaging may provide more practical value than a novel tablet excipient. It can reduce degradation risk, improve dispensing control, and support hospital procurement requirements without changing the active release profile.

Strategy 5: Modified-release or alternative oral delivery

A modified-release busulfan product could reduce peak-related toxicity or dosing variability, but it would require substantial pharmacokinetic and clinical development. The product would likely fall outside a simple ANDA pathway and could require a 505(b)(2) application with additional studies.

This is a high-risk opportunity. The clinical value would need to be demonstrated against existing oral and intravenous busulfan regimens, with particular attention to exposure control and therapeutic drug monitoring.

What patents protect Myleran and busulfan formulations?

The original composition-of-matter protection for busulfan is long expired. Myleran is a legacy product, and its commercial position does not depend on a current basic busulfan patent.

The relevant IP categories are now:

1. Formulation patents covering excipient combinations, release profiles, coatings, or stability.
2. Manufacturing patents covering containment, granulation, compression, or packaging.
3. Method-of-use patents covering conditioning regimens or dosing schedules.
4. Device or administration patents for intravenous busulfan products.
5. Regulatory exclusivity, if any, associated with a newer formulation or indication.

The original Myleran tablet has no practical long-term patent barrier comparable to a recently launched branded oncology product. A current generic applicant should focus on the FDA Orange Book listing, approved labeling, and any active listed patents associated with the specific NDA rather than historical busulfan patent filings.[3]

When does Myleran lose exclusivity?

Myleran’s meaningful brand exclusivity has already expired. Busulfan was approved decades ago, and the original product is not protected by modern new-drug exclusivity periods.

Exclusivity category	Myleran relevance
New chemical entity exclusivity	Expired
Five-year NCE exclusivity	Not applicable to current commercial planning
Three-year clinical-investigation exclusivity	Expired
Orphan-drug exclusivity	Not a current barrier for the legacy tablet
Pediatric exclusivity	No current practical effect
Patent term extension	No meaningful current barrier
Orange Book listed patents	Must be reviewed against the active NDA record
Generic pathway	ANDA is the most direct route for a bioequivalent immediate-release tablet

The practical launch question is therefore not when Myleran loses exclusivity. It is whether an applicant can obtain approval, satisfy cytotoxic manufacturing requirements, and secure reliable supply at a commercially viable price.

What is the Orange Book status of Myleran?

The FDA Orange Book is the controlling source for active NDA, ANDA, therapeutic-equivalence, and listed-patent information.[3] Legacy products can appear with discontinued marketing status even when FDA has not withdrawn approval for safety or efficacy reasons.

For commercial diligence, the relevant checks are:

• Whether the Myleran NDA remains listed as approved or discontinued.
• Whether an active reference listed drug is available for an ANDA.
• Whether an approved busulfan tablet is designated as the reference standard.
• Whether any patent or exclusivity information remains listed.
• Whether the proposed generic can rely on the listed product for bioequivalence.
• Whether a suitability petition or 505(b)(2) route is needed because of formulation or reference-product issues.

If the reference product is not actively marketed, an applicant may face practical difficulties obtaining reference batches for comparative testing. That does not automatically create patent protection, but it can increase development and regulatory execution risk.

What Paragraph IV challenges affect Myleran?

A Paragraph IV challenge is relevant only if an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. Because Myleran is an old busulfan product, the commercial significance of Paragraph IV litigation is likely limited unless a later-listed formulation or use patent remains associated with the reference product.

Potential outcomes include:

• No Paragraph IV filing if no relevant patent is listed.
• A Paragraph III certification with delayed launch until patent expiry.
• A Paragraph IV certification against a formulation or method-of-use patent.
• Declaratory or infringement litigation under the Hatch-Waxman framework.
• Market entry after patent certification without material litigation.

A generic applicant should not treat the historical age of busulfan as proof that no patent work is required. The relevant analysis is product-specific and depends on the current Orange Book record and the applicant’s proposed labeling.

What formulation patents could protect a new busulfan product?

A new formulation could seek patent protection around technical features that produce measurable performance advantages. Candidate areas include:

Stability and packaging

Protection may be available for a composition or packaging system that reduces degradation under defined humidity, temperature, or light conditions. The claims would need to distinguish over conventional tablets and demonstrate a credible technical effect.

Low-dose content uniformity

A formulation that uses a specific particle-engineering method, ordered mixture, carrier system, or granulation process may support patent claims if it produces superior uniformity at the 2 mg strength.

Modified release

Polymers, multiparticulates, osmotic systems, or coated pellets could support claims directed to release kinetics. Clinical and pharmacokinetic evidence would be needed to support commercial differentiation.

Reduced occupational exposure

A coated tablet, sealed unit-dose presentation, or manufacturing process that reduces dust generation could create a valuable manufacturing and handling position. Such claims may be more defensible as process or packaging claims than as broad composition claims.

Alternative excipient profile

A lactose-free, titanium-dioxide-free, or preservative-free product can support commercial positioning, but excipient substitution alone usually provides weak patent scope unless linked to a defined technical result.

How strong is the Myleran patent estate?

The legacy Myleran patent estate is weak as a barrier to generic entry because the underlying active ingredient and original tablet technology are old. The stronger opportunities are in narrowly defined reformulations, manufacturing controls, and packaging systems.

IP factor	Assessment
Busulfan composition-of-matter protection	Expired
Original immediate-release tablet	Weak current exclusivity position
Novel excipient combination	Potentially protectable but likely narrow
Modified-release product	Stronger potential IP, higher development cost
Cytotoxic containment process	Potential process protection
High-barrier packaging	Potentially protectable, but design-around risk is high
Method of use	Dependent on current patent and labeling scope
Generic entry barrier	Regulatory and manufacturing execution, not basic patent rights

A new entrant should value manufacturing know-how, analytical methods, supply agreements, and oncology-distribution relationships alongside formal patents.

What generic entry risks exist for Myleran?

Generic entry risk is high from a patent perspective, but not necessarily simple from an operational perspective.

Regulatory risk

The applicant must establish pharmaceutical equivalence and bioequivalence for the proposed tablet. Changes in excipient composition are acceptable only if the product meets the applicable quality and bioequivalence requirements.

Manufacturing risk

Busulfan is a potent cytotoxic compound. Facilities may require dedicated controls, validated cleaning, closed transfer, dust suppression, worker-protection procedures, and segregation from non-cytotoxic products.

Supply risk

A commercially viable product requires secure busulfan API supply, consistent particle-size control, qualified excipient suppliers, and robust packaging components. Shortages or supplier changes can create outsized risk in a low-volume oncology product.

Market risk

The market may be small relative to high-volume generic medicines. Hospitals and specialty distributors may prioritize continuity of supply over minor formulation differences. A new entrant must therefore compete on reliable availability, quality history, pricing, and service.

Which companies are challenging or competing with Myleran?

The relevant competitors are generic busulfan suppliers and manufacturers of alternative busulfan dosage forms. The competitive field includes:

• Generic manufacturers of oral busulfan tablets.
• Manufacturers or licensees of intravenous busulfan.
• Contract manufacturers with cytotoxic handling capability.
• Specialty oncology distributors.
• Potential 505(b)(2) developers pursuing modified-release or patient-specific formulations.

The specific active suppliers can change by country and over time. FDA’s Drugs@FDA database, Orange Book, DailyMed, and national marketing authorization databases provide the controlling product-level records.[1,3,4]

How does oral Myleran compare with intravenous Busulfex?

Attribute	Oral Myleran	Intravenous busulfan
Dosage form	2 mg tablet	Sterile injectable solution
Development pathway	Usually ANDA for equivalent tablet	ANDA or 505(b)(2), depending on product
Main use context	Historical chronic oral therapy	Conditioning before hematopoietic stem-cell transplantation
Excipient challenge	Content uniformity, dissolution, stability	Sterility, endotoxin, particulate control, infusion compatibility
Manufacturing burden	High-potency solid-dose controls	Aseptic or terminal-sterilization strategy, depending on formulation
Clinical control	Oral absorption variability	Controlled intravenous exposure
Commercial differentiation	Supply, tolerability, packaging, excipient profile	Pharmacokinetic control and transplant-center adoption

The intravenous market has a stronger clinical value proposition in transplantation, while the oral tablet offers a lower-cost solid-dose opportunity if demand and reference-product access support commercial launch.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve manufacturing capability and regional commercialization than ownership of the legacy Myleran brand.

Potential deal structures include:

• Regional rights for an approved generic busulfan tablet.
• Contract manufacturing by a facility qualified for cytotoxic products.
• Supply agreements for micronized or particle-engineered busulfan API.
• Licensing of a modified-release oral formulation.
• Co-development of a high-barrier, unit-dose oncology package.
• Distribution partnerships with specialty oncology wholesalers.

A licensee should assess freedom to operate across composition, manufacturing, packaging, and method-of-use claims. For a legacy product, the value of a transaction will usually depend on approval status, API security, manufacturing compliance, and market access rather than historical brand recognition.

What FDA regulatory status applies to a new Myleran generic?

A conventional 2 mg immediate-release tablet would generally be evaluated through the ANDA pathway if a suitable reference listed drug and product-specific guidance are available. A materially different formulation, new route, new dosage form, or new clinical use may require a 505(b)(2) application.

Key regulatory workstreams include:

• Pharmaceutical equivalence.
• Comparative dissolution.
• Bioequivalence.
• Assay and content uniformity.
• Degradation-product control.
• Stability under ICH conditions.
• Cytotoxic manufacturing validation.
• Cleaning-validation and cross-contamination controls.
• Labeling consistency with the reference product.
• Packaging qualification.
• Post-approval change management.

The most efficient product is usually a reference-aligned immediate-release tablet with a differentiated supply and packaging proposition rather than a highly novel excipient system.

Key Takeaways

• Myleran is the legacy oral busulfan 2 mg tablet.
• Its original active-ingredient and brand exclusivity have expired.
• The principal excipient platform is a conventional lactose-starch tablet with magnesium stearate, glidant, and film-coating components.
• The most important formulation issue is low-dose content uniformity for a potent cytotoxic compound.
• A lactose-free or improved-barrier formulation could support commercial differentiation, but excipient substitution alone is unlikely to create strong patent protection.
• Generic entry risk is low from a basic patent perspective and higher from manufacturing, API supply, regulatory, and market-size perspectives.
• A conventional ANDA is the likely lowest-cost route for an equivalent immediate-release tablet.
• Modified-release, improved-stability, and occupational-exposure-reduction products offer greater IP potential but require more extensive development.
• Oral Myleran and intravenous busulfan address different clinical and commercial segments.
• The strongest commercial assets are likely to be reliable supply, cytotoxic manufacturing capability, packaging control, and specialty oncology distribution.

FAQs

Is busulfan still available as an oral tablet?

Oral busulfan may be available through generic or regional products, but product availability varies by jurisdiction. Myleran is a legacy brand, and current supply should be evaluated through national regulatory and pharmaceutical distribution records.

Can a generic busulfan tablet use different excipients from Myleran?

Yes. A generic may use different inactive ingredients if it meets applicable pharmaceutical equivalence, bioequivalence, quality, safety, and labeling requirements. The applicant must demonstrate that the changes do not adversely affect performance.

Is busulfan a good candidate for a 505(b)(2) product?

Busulfan can support a 505(b)(2) strategy if the proposed product introduces a materially different dosage form, release profile, route, or clinically relevant formulation advantage. A conventional equivalent tablet is generally better suited to the ANDA pathway.

What is the main manufacturing barrier for busulfan tablets?

The principal barrier is safe and validated handling of a potent cytotoxic API. Containment, dust control, cleaning validation, cross-contamination prevention, and worker protection are central to commercial production.

Could a lactose-free Myleran formulation obtain patent protection?

A lactose-free composition could be patentable only if it includes a novel and non-obvious formulation or process with a defensible technical effect. Lactose removal by itself would generally provide limited patent strength.

References

1. DailyMed. (n.d.). Myleran: Busulfan tablet, film coated, product labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2015). ANDA submissions: Content and format of abbreviated new drug applications. FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
5. U.S. Food and Drug Administration. (2016). Considerations in demonstrating interchangeability with a reference product: Guidance for industry. FDA.